108: Advancing the Genetic Pool of Parkinson Disease

NeurologyLive® Mind Moments®

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice.
In this episode, Igancio Mata, PhD, sat down to discuss a recently published meta-analysis on the genetic backgrounds of Parkinson disease beyond traditional European populations. Mata, an associate professor in the Genomic Medicine Institute at Cleveland Clinic, provided insight on the newly identified novel loci and how the data adds to previous genome-wide association studies. In addition, he gave thoughts on the possibility of gene therapy and some of the barriers that come with it, as well as the feasibility of incorporating genetic checkpoints into clinical trial inclusion criteria.
Looking for more movement disorder discussion? Check out the NeurologyLive® movement disorder clinical focus page.
Episode Breakdown:

• 1:10 – Meta-analysis overview
• 3:20 – Significance of results, how they add to the literature
• 6:50 – Feasibility of incorporating genetic screening into clinical trials
• 8:40 – Neurology News Minute
• 11:15 – Realistic expectations and potential with gene therapy
• 15:45 – Next steps in advancing this research

This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com.
The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here:

• Biogen Walks Away From Aducanumab to Prioritize Lecanemab and Alzheimer Disease Pipeline

• Updated Guidelines Published to Improve Care in Specialized Epilepsy Centers

• FDA Clears IND for Gene Therapy Candidate ETX101 in Dravet Syndrome

Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.